About Tivic
Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivics patented technology platform leverages stimulation on the
trigeminal, sympathetic, and vagus nerve structures. Tivics non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free
therapeutic solutions with high safety profiles, low risk, and broad applications. Tivics first commercial product, ClearUP, is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven,
doctor-recommended, and is available through online retailers and commercial distributors. For more information, visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may
contain forward-looking statements that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking
statements contained in this press release may be identified by the use of words such as anticipate, believe, contemplate, could, estimate, expect, intend,
seek, may, might, plan, potential, predict, project, target, aim, should, will would, or the negative of
these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.s current expectations and are subject to inherent uncertainties,
risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors, including, without limitation: market, economic and other conditions; supply chain constraints; macroeconomic factors, including inflation; the companys ability to raise additional
capital on favorable terms; changes in regulatory requirements; and unexpected costs, charges or expenses that reduce Tivics capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivics actual results to differ from those contained in the forward-looking statements, see Tivics
filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading Risk Factors, as well as the
companys subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com